AeroLeads people directory · profile
Brian Jahns Email & Phone Number
President, and Chief Executive Officer
at
Vasomune Therapeutics, Inc.
1 work email found
@vasomune.com
3 phones found area 973 and 416
LinkedIn matched
✓ Verified August 2026
4 data sources
Profile completeness 100%
Current company
Role
President, and Chief Executive Officer
Location
Greater Toronto Area, Canada
Company size
Who is Brian Jahns? Overview
A concise factual answer block for searchers comparing this professional profile.
Quick answer
Brian Jahns is listed as President, and Chief Executive Officer at Vasomune Therapeutics, Inc., a with 9 employees, based in Greater Toronto Area, Canada. AeroLeads shows a work email signal at vasomune.com, phone signal with area code 973, 416, and a matched LinkedIn profile for Brian Jahns.
Brian Jahns previously worked as President, and Chief Operating Officer at Vasomune Therapeutics, Inc. and Consultant in Oncology and Rare Diseases Biotechnology and Managing Director, DynEq Consulting Inc. at Dyneq Consulting Inc.. Brian Jahns holds Executive Program from Queen'S University.
Company email context
Email format at Vasomune Therapeutics, Inc.
This section adds company-level context without repeating Brian Jahns's masked contact details.
{first_initial}{last}@vasomune.com
89% confidence
AeroLeads found 1 current-domain work email signal for Brian Jahns. Compare company email patterns before reaching out.
Profile bio
About Brian Jahns
I believe that we succeed only if we place patients at the centre of everything we do. I deeply understand the needs of patients, and use this insight to help save lives. I've worked successfully on both sides of the pharma equation: as healthcare provider, and as pharma executive working in commercial and medical roles.I bring a strategic mindset to the table, and am able to prioritize and execute with limited resources. I'm able to roll up my sleeves and carry out tactical work needed to execute while simultaneously providing the strategic thinking necessary to fulfill a corporate vision.My values enable me to grow, coach effectively, and drive results. I model authenticity, passion, and integrity. By modelling authenticity and approachability, I engage customers and employees to focus on a vision of improving patient outcomes. In my experience, great ideas come from a variety of sources. By being approachable and authentic, I maximize the value that individuals offer, and I spur them to act with more confidence.I communicate passion for my work, and inspire others to greatness. I believe that as a healthcare provider, I used to care for patients one at a time. Now, as a corporate leader in biotech, I deliver on the promise of personalized medicine and care for patients on a broader scale. By valuing and modelling integrity, I motivate others to act ethically.Together, we put the interests of patients and the organization first, and we generate value in an ethical and sustainable manner.Contact me at: bejahns(@)gmail.com
Listed skills include Oncology, Pharmaceutical Industry, Biotechnology, Pharmaceutical Sales, and 51 others.
Current workplace
Brian Jahns's current company
Company context helps verify the profile and gives searchers a useful next step.
Vasomune Therapeutics, Inc.
20 roles · 35 years
Brian Jahns work experience
A career timeline built from the work history available for this profile.
President, And Chief Operating Officer
Current
May 2023 - Present
Consultant In Oncology And Rare Diseases Biotechnology And Managing Director, Dyneq Consulting Inc.
CurrentDynamic Equilibrium: Early stage biotech companies will appreciate our ability to integrate science, and patient and stakeholder needs with business priorities. We provide strategic insight and direction, and execute decisively. Decades of experience and success have enabled us to develop capability and expertise in:- Strategic planning,- Oncology development and commercialization,- Rare and orphan disease therapeutics development and commercialization,- Licensing and partnering.
Jul 2016 - Present
Board Director, N-Zyme Biomedical Inc.
Dec 2022 - Dec 2023
Board Director, Sauvie Bike Llc
Dec 2022 - Dec 2023
Chief Operating Officer, Sauvie Inc.
Sauvie Inc. is an emerging global biopharma company executing a diversified risk, high growth strategy in immuno-oncology development and commercialization.
Feb 2022 - Dec 2023
Senior Vice-President, Commercial And Business Development
Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s lead program, TTI-621, is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (“do not eat”) signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (“eat”) signals. A Phase 1 clinical trial (NCT02663518) evaluating intravenous dosing of SIRPaFc in patients with advanced cancer is ongoing, and a second Phase 1 trial evaluating direct intratumoral injections is underway in solid tumors and mycosis fungoides (NCT02890368). TTI-622 is an IgG4 SIRPaFc protein, which is primarily being developed for combination therapy. Trillium also has a proprietary medicinal chemistry platform, using unique fluorine chemistry, which permits the creation of new chemical entities from validated drugs and drug candidates with improved pharmacological properties. Stemming from this platform, the company’s most advanced preclinical programs are: 1. STING agonist, TTI-10001, a non-cyclic dinucleotide STING agonist that may be dosed intratumorally, intravenously, and orally. 2. TTI-2341, an orally-available epidermal growth factor receptor (EGFR) antagonist with increased uptake and retention in the brain. In addition, a number of compounds directed at undisclosed immuno-oncology targets are currently in the discovery phase.
Oct 2016 - Dec 2019
Vice-President, Sales And Marketing, Oncology (Canada) & Vice-President, Product Strategy (Canada)
• Led twenty-three marketing and fifty-one field reports in the successful launches of Gazyva, Zelboraf, Erivedge, Perjeta, Kadcyla, and Cotellic.• Active in the Canadian Leadership Team executive committee reporting to the CEO.• Led the design and implementation of marketing strategy, sales promotion and local life-cycle team management for Rituxan, Herceptin, Avastin, Xeloda, and Tarceva. As a result, grew sales from $420M in 2011 to $560M in 2015, achieving standings of 1st, 2nd, and 3rd largest Canadian brands in the hospital space.• Led marketing development of product digital channels and social media plans.• These efforts resulted in the successful uptake of Perjeta in first line metastatic HER2+ve breast cancer. These efforts also resulted in the successful launch of Zelboraf complimented by a unique national melanoma BRAF testing service.• Led the Key Account Management function, an innovative Pharma and Diagnostics partnership designed to augment the corporate value proposition and relationships with senior hospital stakeholders, including the C-suite.• Led focus on enhancing customer value and satisfaction.• Active in a wide range of critical organizational activities including the Roche 2020 corporate reorganization, which positioned marketing and sales for greater future success. The result of these efforts was a reorganization in commercial staff that enabled the organization to service customers in a more efficient manner.
Aug 2011 - Jul 2016
Business Unit Director, Hematology
Nov 2006 - Aug 2011
Marketing Director, Hematology
Jan 2006 - Nov 2006
Associate Medical Director, Hematology & Oncology
Apr 2003 - Jan 2006
Marketing And Sales Manager, Virology
Jan 2001 - Apr 2003
Associate Medical Director, Infectious Diseases
Oct 1998 - Dec 2001
Senior Associate
Phase 4 Health Inc
Jan 1997 - Oct 1998
Vice Chair, Ethics Review Committee
Integrated Research Inc.
Jan 1996 - Jan 1998
Clinical Instructor, Doctor Of Pharmacy Program
Jan 1995 - Jan 1997
Faculty Member Of Research Ethics Board
Jan 1996 - Dec 1996
Clinical Pharmacy Specialist, Trauma And Neurosurgical Intensive Care Unit
May 1995 - Dec 1996
Research Fellow, Dept Of Pharmacy Practice, & Clinical Associate, Program In Emergency Medicine
1993 - 1995
~2 yrs
Pharmacy Practice Resident, Detroit Receiving Hospital
1992 - 1993
~1 yr
6 education records
Brian Jahns education
Executive Program
Queen'S University
Doctor Of Pharmacy - Pharmd
Wayne State University
Bachelor Of Pharmacy - Bpharm
Wayne State University
Bachelor Of Science - Bs
Western University
Pharma Marketing Program
Insead
Venture Finance Programme, 2021
Saïd Business School, University Of Oxford
FAQ
Frequently asked questions about Brian Jahns
Quick answers generated from the profile data available on this page.
What company does Brian Jahns work for?
Brian Jahns works for Vasomune Therapeutics, Inc..
What is Brian Jahns's role at Vasomune Therapeutics, Inc.?
Brian Jahns is listed as President, and Chief Executive Officer at Vasomune Therapeutics, Inc..
What is Brian Jahns's email address?
AeroLeads has found 1 work email signal at @vasomune.com for Brian Jahns at Vasomune Therapeutics, Inc..
What is Brian Jahns's phone number?
AeroLeads has found 3 phone signal(s) with area code 973, 416 for Brian Jahns at Vasomune Therapeutics, Inc..
Where is Brian Jahns based?
Brian Jahns is based in Greater Toronto Area, Canada while working with Vasomune Therapeutics, Inc..
What companies has Brian Jahns worked for?
Brian Jahns has worked for Vasomune Therapeutics, Inc., Dyneq Consulting Inc., N-Zyme Biomedical Inc., Sauvie Inc., and Trillium Therapeutics Inc..
Who are Brian Jahns's colleagues at Vasomune Therapeutics, Inc.?
Brian Jahns's colleagues at Vasomune Therapeutics, Inc. include Harold Kim and Gosia Hodgson, Cpa, Ca.
How can I contact Brian Jahns?
You can use AeroLeads to view verified contact signals for Brian Jahns at Vasomune Therapeutics, Inc., including work email, phone, and LinkedIn data when available.
What schools did Brian Jahns attend?
Brian Jahns holds Executive Program from Queen'S University.
What skills is Brian Jahns known for?
Brian Jahns is listed with skills including Oncology, Pharmaceutical Industry, Biotechnology, Pharmaceutical Sales, Clinical Trials, Infectious Diseases, Hematology, and Strategy.
Find 750M verified contacts
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial